LFCR earnings analysis
What we found in LFCR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Lifecore generated $34.167 million of quarterly revenue, down $2.277 million (6%) from the comparable prior-year period, as a 34% CDMO decline outweighed 44% HA manufacturing growth. Gross margin contracted 3.1 percentage points to 35.3%, although the company posted operating income of $2.567 million and six-month operating cash flow of $2.511 million. The principal overhang is capital structure risk: approximately $198.1 million of Alcon indebtedness and $50.2 million of preferred stock submitted for redemption, versus $38.8 million of consolidated liquidity.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- HA manufacturing grew 44%
- Quarterly HA manufacturing revenue increased 44% to $18.615 million, partially offsetting a $7.964 million (34%) CDMO revenue decline.
- Operations remained profitable
- Gross margin was 35.3%, down 3.1 percentage points from 38.4%, while operating income was $2.567 million, or a 7.5% operating margin, despite a 6% revenue decline.
- Positive operating cash generation
- Operating cash flow was positive at $2.511 million for the six months ended June 30, 2026; investing outflows were $1.631 million.
- Revolver capacity supports liquidity
- Liquidity totaled $38.8 million at June 30, comprising $17.2 million of cash and $21.6 million of revolver availability; the $40.0 million revolver had no borrowings outstanding.
- Efficiency program is advancing
- Management reported more than 40 cost-reduction or productivity projects progressed through June 30, 2026, following implementation of a new ERP system in January 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Large preferred-stock redemption obligation
- All 49,263 preferred shares have submitted redemption notices, representing a $50.2 million aggregate liquidation preference as of June 30, 2026. Redemptions are due December 28, 2026, and any unpaid balance incurs 1% monthly interest in addition to 7.5% annual PIK dividends.
- High debt burden and rising interest cost
- Total Alcon indebtedness was approximately $198.1 million, including $192.7 million under the term loan at a 20.9% effective annual interest rate. Net interest expense rose 38% to $7.607 million in the quarter.
- CDMO demand and project-timing pressure
- CDMO revenue fell 34% to $15.552 million, driven by $5.9 million of lower sales volume, $1.2 million less development revenue, and a $0.9 million prior-year take-or-pay arrangement.
- Material weakness remains unremediated
- Disclosure controls and procedures remained ineffective at June 30, 2026 because the prior material weakness in ERP-related IT general controls had not been fully remediated.
- No formal risk-factor updates
- The filing reports no material changes to risk factors from the 2025 Transition Report, but six-month revenue declined 20% to $57.360 million and gross margin contracted 4.5 percentage points to 28.8%.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.19
- Gross margin
- 35.3%
- Operating margin
- 7.5%
- Segment
- CDMO revenue: $15.552 million, down $7.964 million (34%) versus $23.516 million.
- Segment
- HA manufacturing revenue: $18.615 million, up $5.687 million (44%) versus $12.928 million.
What they said about what is next.
The 10-Q does not provide quantitative revenue or EPS guidance. Management states that existing cash, operating cash generation, and revolver availability are expected to fund operational and capital requirements for at least the next 12 months.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 6, 2026
- Lifecore Biomedical reported Q1 2026 earnings with revenues of $23.2 million, significantly below the estimate of $26.3 million, and an EPS of -$0.43, missing the consensus estimate of -$0.28. The firm has reaffirmed…
- 10-Q · November 6, 2025
- Lifecore Biomedical reported significant revenue growth in Q1 2026, totaling $31.1 million, a 26% increase compared to $24.7 million in the same period last year. Despite the growth, the company faces challenges with…
- 10-K · August 7, 2025
- Lifecore Biomedical's fiscal 2025 results show stable revenue performance driven by growth in HA manufacturing, which increased by 23% to $38.8 million, albeit offset by a 7% decline in CDMO revenues. The Company…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LFCR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever